Imugene’s onCARlytics combination with placenta-derived…
SYDNEY, Australia and FLORHAM PARK, NJ, November 10, 2022 (GLOBE NEWSWIRE) — Imugene Limited IMUa clinical-stage immuno-oncology company, and Celularity Inc. CELU (Celularity), a clinical-stage